Positive association between striatal serotonin level and abnormal involuntary movements in chronic l-DOPA-treated hemiparkinsonian rats

Brain Research Bulletin

Volumn 84, Issue 2, 2011, Pages 151-156

  Gil, Suk J ^a   Park, Chang H ^a   Lee, Jeong E ^a   Minn, Yang K ^b   Koh, Hyun C ^a  

^a Hanyang University   (South Korea)

^b Hallym University   (South Korea)

Author keywords

5 Hydroxytryptamine; Abnormal involuntary movement score; Dopamine; L DOPA induced dyskinesia; Parkinson's disease

Indexed keywords

BENSERAZIDE; DOPAMINE; LEVODOPA; OXIDOPAMINE; SEROTONIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN DAMAGE; CHRONIC DISEASE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DYSKINESIA; FEMALE; LONG TERM CARE; MEDIAL FOREBRAIN BUNDLE; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL; RAT; SEROTONIN BLOOD LEVEL; SEROTONIN BRAIN LEVEL; SEROTONINERGIC SYSTEM;

ANIMALS; BENSERAZIDE; CORPUS STRIATUM; DOPAMINE; DOPAMINE AGENTS; DYSKINESIA, DRUG-INDUCED; FEMALE; LEVODOPA; MEDIAL FOREBRAIN BUNDLE; OXIDOPAMINE; PARKINSON DISEASE; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN;

EID: 79451472803     PISSN: 03619230     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainresbull.2010.12.006     Document Type: Article

References (31)

1. Ahlskog J.E., Muenter M.D. Frequency of levodopa-related dyskinesias and motor fluctutations as estimated from the cumulative literature. Mov. Disord. 2001, 16:448-458.
2. 1 agonist SKF 82958. Behav. Pharmacol. 1999, 10:175-182.
3. Anton A.H., Sayre D.F. A study of the factors affecting the aluminum oxide-trihydroxyindole procedures for the analysis of catecholamine. J. Pharamcol. Exp. Ther. 1962, 138:360-375.
4. Arai R., Karasawa N., Geffard M., Nagatsu T., Nagatsu I. Immunohistochemical evidence that central serotonin neurons produce dopamine from exogenous l-DOPA in the rat, with reference to the involvement of aromatic L-amino acid decarboxylase. Brain Res. 1994, 667:95-299.
5. 1A agonist in advanced Parkinson's disease. Mov. Disord. 2005, 20:932-936.
6. 1A agonist improves motor complications in rodent and primate parkinsonian models. Neurology 2001, 57:1829-1834.
7. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 1976, 72:248-254.
8. 2-dopamine agonists into nucleus accumbens and striatum without changing dopamine antagonist binding. Pharmacol. Exp. Ther. 1987, 240:167-176.
9. Carlsson T., Carta M., Winkler C., Björklund A., Kirik D. Serotonin neuron transplants exacerbate l-DOPA-induced dyskinesias in a rat model of Parkinson's disease. J. Neurosci. 2007, 27:8011-8022.
10. Carta M., Carlsson T., Kirik D., Bjorklund A. Dopamine released from 5-HT terminals is the cause of l-DOPA-induced dyskinesia in parkinsonian rats. Brain 2007, 130:1819-1833.
11. Carta M., Lindgren H.S., Lundblad M., Stancampiano R., Fadda F., Cenci M.A. Role of striatal l-DOPA in the production of dyskinesia in 6-hydroxydopamine lesioned rats. J. Neurochem. 2006, 96:1718-1727.
12. Cenci M.A. Transcription factors involved in the pathogenesis of l-DOPA-induced dyskinesia in a rat model of Parkinson's disease. Amino acids 2002, 23:105-109.
13. Cenci M.A., Lee C.S., Björklund A. l-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA. Eur. J. Neurosci. 1998, 10:2694-2706.
14. 1A receptor stimulation on dopamine receptor-mediated abnormal involuntary movements and rotations in the primed hemiparkinsonian rat. Brain Res. 2007, 1158:135-143.
15. 1A agonist buspirone reduces the expression and development of l-DOPA-induced dyskinesia in rats and improves l-DOPA efficacy. Pharmacol. Biochem. Behav. 2007, 87:306-314.
16. de la Fuente-Fernandez R., Schulzer M., Mak E., Calne D.B., Stoessl A.J. Presynaptic mechanisms of motor fluctuations in Parkinson's disease; a probabilistic model. Brain 2004, 127:888-899.
17. Gil S.J., Park C.H., Lee J.E., Koh H.C. The roles of striatal serotonin and L-amino-acid decarboxylase on l-DOPA-induced dyskinesia in a hemiparkinsonian rat model. Cell. Mol. Neurobiol. 2010, 30:817-825.
18. 1 receptor blockade improves l-DOPA-induced dyskinesia but worsens parkinsonism in MPTP monkeys. Neurology 1999, 52:771-776.
19. Hurley M.J., Jenner P. What has been learnt from study of dopamine receptors in Parkinson's disease?. Pharmacol. Ther. 2006, 111:715-728.
20. Lee C.S., Cenci M.A., Schulzer M., Björklund A. Embryonic ventral mesencephalic grafts improve levodopa-induced dyskinesia in a rat model of Parkinson's disease. Brain 2000, 123:1365-1379.
21. Lundblad M., Andersson M., Winkler C., Kirik D., Wierup N., Cenci M.A. Pharmacological validation of behavioral measures of akinesia and dyskinesia in a rat model of Parkinson's disease. Eur. J. Neurosci. 2002, 15:120-132.
22. Maeda T., Kannari K., Shen H., Arai A., Tomiyama M., Matsunaga M., Suda T. Rapid induction of serotonergic hyperinnervation in the adult rat striatum with extensive dopaminergic denervation. Neurosci. Lett. 2003, 343:17-20.
23. Mink J.W. The basal ganglia; focused selection and inhibition of competing motor programs. Prog. Neurobiol. 1996, 50:381-425.
24. Miller R., Beninger R.J. On the interpretation of asymmetries of posture and locomotion produced with dopamine agonists in animal with unilateral depletion of striatal dopamine. Prog. Neurobiol. 1991, 36:229-256.
25. Nicholas A.P., Buck K., Ferger B. Effects of levodopa on striatal monoamines in mice with levodopa-induced hyperactivity. Neurosci. Lett. 2008, 443:204-208.
26. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates 1986, Academic Press, San Diego.
27. Rascol O., Brooks D.J., Korczyn A.D., De Deyn P.P., Clarke C.E., Lang A.E. A five-years study of the incidence of dyskinesia in patients with early Parkinson's disease who were treat with ropinirole or levodopa. N. Engl. J. Med. 2000, 342:1484-1491.
28. Stocchi F., Nordera G., Marsden C.D. Strategies for treating patient with advanced Parkinson's disease with disastrous fluctuation and dyskinesias. Clin. Neuropharmacol. 1997, 20:95-115.
29. Takeuchi Y., Sawada T., Blunt S., Jenner P., Marsden C.D. Effects of 6-hydroxydopamine lesions of the nigrostriatal pathway on striatal serotonin innervation in adult rats. Brain Res. 1991, 562:301-305.
30. Tanaka H., Kannari K., Maeda T., Tomiyama M., Suda T., Matsunaga M. Role of serotonergic neurons in l-DOPA-derived extracelluar dopamine in the striatum of 6-OHDA-lesioned rats. Neuroreport 1999, 10:631-634.
31. 2 receptor contributions to l-DOPA-induced dyskinesia in the dopamine depleted rat. Pharmacol. Biochem. Behav. 2005, 81:887-893.